A Study of LY3532226 in Participants With Obesity

NCT06557356 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: LY3532226
DRUG: Placebo

Sponsor

Eli Lilly and Company